Delivering drugs to the right place: Targeted drug delivery method could potentially slow progression of polycystic kidney disease - (Science Daily via NewsPoints Desk)

  • Scientists have developed a method to potentially target therapeutic antibodies to polycystic kidneys, opening up the possibility of repurposing existing drugs to treat the condition, Science Daily reported.
  • The research, published in the Journal of Biological Chemistry, details a method that enables antibodies from the immunoglobulin-A (IgA) class to penetrate the cyst wall.
  • The research team found that when they injected IgA into mice, about 7 percent of the injected IgA remained inside the cyst lumens of polycystic kidneys.
  • Lead author Thomas Weimbs said "this suggests that the IgA gets taken up and is trapped inside because these cysts don't have an exit. So we end up with a way of exploiting the pIgR system for targeting these antibodies specifically to the polycystic kidney."
  • The scientists noted that the key is using molecular cloning to reformat an existing IgG antibody to IgA, then the pIgR system carries the IgA antibody inside the cyst, where it neutralises a specific receptor.
  • "Our strategy allows for the repurposing of thousands of existing monoclonal antibodies that have already been developed, which opens up a whole new class of therapeutics not previously used for PKD therapy," Weimbs concluded.

To read more NewsPoints articles, click here.